Jun. 10 at 8:08 PM
JPMorgan upgraded Illumina to Overweight from Neutral and raised its December 2026 price target to
$185 from
$125, citing stronger confidence in the DNA sequencing company's ability to sustain growth despite increasing competition. The bank said concerns about customers switching to rival platforms have eased, supported by industry checks showing that major clinical clients remain committed to Illumina's ecosystem.
Surveys of research and clinical customers pointed to accelerating spending on sequencing instruments and consumables in 2027 and 2028, with expectations for Illumina to gain market share in next-generation sequencing. JPMorgan highlighted structural growth drivers such as precision medicine, minimal residual disease monitoring, and multi-cancer early detection testing, alongside rising adoption of whole-genome sequencing and multiomics workflows.
$ILMN $JPM